Clinical trial
A Phase 1a/1b, Multi-center, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier CC-122 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma.
NCT01421524 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1a/1b, Multi-center, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier CC-122 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma.
- Lead sponsor
- Celgene
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 12, 2011
- Completion date
- November 21, 2023
- Enrollment
- 271 (actual)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.
glioblastoma, lymphoma, lymphoma, large b-cell, diffuse, multiple myeloma, pleiotropic pathway modifier, primary central nervous system lymphoma